glp 1 lawsuit update Hims & Hers Health (HIMS) Securities Class Action Ozempic® Lawsuit | July 2026

Description

Tirzepatide is not recommended during pregnancy

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

A GLP-1-friendly snack passes ALL criteria in both sections

The highest return on capital over the next decade will likely sit with the owners of the difficult parts of the chain: the innovators with next-gen IP and the specialized manufacturers (CDMOs/Device Makers) who can solve the persistent fill-finish bottleneck

In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Recommended: Prepare an additional quantity of animals to account for potential losses during experiments